|
|
Post by harryx1 on Feb 11, 2016 11:15:02 GMT -5
Everyone that has a twitter account should favorite and re-tweet this!  |
|
|
|
Post by peppy on Feb 11, 2016 11:22:15 GMT -5
Oh good. Thank you Harry. Someone with a powerful voice. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 11, 2016 11:24:13 GMT -5
Its nice to see more new faces
|
|
|
|
Post by dreamboatcruise on Feb 11, 2016 12:25:03 GMT -5
He's in NJ. Wonder if he knows where the first of the clinics is opening. Maybe JDRF is involved in them.
I often wondered whether some of the associations such as JDRF might be persuaded to get behind Afrezza... but I had suspected that maybe they were beholden to the big pharma diabetes companies. Encouraging that this guy is being public about his experience... obviously he isn't in the pocket of Novo or Lilly.
|
|
|
|
Post by bradleysbest on Feb 11, 2016 12:42:24 GMT -5
Can those posts be tagged on to the MNKD twitter & FB accounts? Good stuff!
|
|
|
|
Post by mindovermatter on Feb 11, 2016 12:56:27 GMT -5
He's only been on it for 5 weeks? Why did he wait so long to get on it?! I wonder if JDRF will start doing some soft pushing of it? It will also be interesting to see if he ends up ditching his pump.
|
|
|
|
Post by dreamboatcruise on Feb 11, 2016 12:59:14 GMT -5
Can those posts be tagged on to the MNKD twitter & FB accounts? Good stuff! From Matt's comments it would appear no. |
|
|
|
Post by dreamboatcruise on Feb 11, 2016 14:11:28 GMT -5
He's only been on it for 5 weeks? Why did he wait so long to get on it?! I wonder if JDRF will start doing some soft pushing of it? It will also be interesting to see if he ends up ditching his pump. Probably took that long to get insurance approval. |
|
|
|
Post by compound26 on Feb 11, 2016 15:37:57 GMT -5
Dr. Aaron Kowalski was one of the 17 public speakers spoke at the 2014 AdCom supporting FDA's approval of Afrezza. diatribe.org/issues/63/new-now-next/1The diaTribe team was onsite during the meeting, as Editor-in-Chief Kelly Close and Managing Editor Adam Brown spoke as patients during the Open Public Hearing (OPH). Both advocated in favor of patients being given a wider range of treatment options, including Afrezza. See Adam’s slides here, and Kelly’s talk and slides here and here. An impressive 17 speakers came to the OPH to speak on behalf of Afrezza (the largest ever for a diabetes-related therapy), and all noted the importance of increasing treatment options for patients and improving the patient experience. We found it to be an incredibly powerful session, one that included leaders Dr. Aaron Kowalski from JDRF, Dr. Robert Ratner from ADA, Dr. Steve Edelman of TCOYD, Bennet Dunlap of Strip Safely, and the legendary Dr. Lois Jovanovič of Sansum Diabetes, a renowned researcher whose trip was paid for by patients who wanted to cover the costs of her testimony. Manny Hernandez of the Diabetes Hands Foundation was also able to testify via webcast – a first for the FDA and an impressive diabetes advocacy achievement. You can view a recording of his testimony here and read more great quotes we heard at the OPH in our quotable quotes this issue. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM397049.pdfThere is an informative interview of Dr. Aaron Kowalski published by diaTribe. diatribe.org/diatribe-exclusive-interview-dr-aaron-kowalski-jdrf-first-ever-chief-mission-officerPer the interview, "as Chief Mission Officer, Aaron plans that his top priority will be working closely with JDRF’s team to ensure that new treatments get into the hands of people with diabetes more quickly. Additionally, Aaron’s new role will allow him to work as a bridge between the community of people impacted by type 1 diabetes and all that JDRF is doing on the research and advocacy fronts. No one is better positioned to do so, given his deep scientific knowledge of type 1 diabetes, his valuable, decade-long experience at JDRF, his patient perspective from nearly 30 years of type 1 diabetes and a close family member (his brother) for nearly 40 years, and a never-ending drive to make life better for people with diabetes. JDRF’s mission is to “turn type one into type none,” and with this new promotion, we are confident that Dr. Kowalski is the very best choice to make that mission a reality." |
|
|
|
Post by jpg on Feb 11, 2016 15:46:04 GMT -5
From my perspective this type of advocacy is the only way forward for Afrezza.
|
|
|
|
Post by dreamboatcruise on Feb 11, 2016 15:50:40 GMT -5
Everyone that has a twitter account should favorite and re-tweet this! LOL... how would I know if the ONE person following me on twitter would be interested in this? It would seem important to get my content right because I could easily lose my ENTIRE audience with one misstep. |
|
|
|
Post by LosingMyBullishness on Feb 11, 2016 15:58:40 GMT -5
Compound26,
no offence meant: Do you understand why none of these people had a significant positive influence on endos picking up Afrezza?
I realize that this past endorsement encouraged MNKD management to believe that sales to Afrezza would soar right after start of sales.
Where were these people last year?
|
|
|
|
Post by compound26 on Feb 11, 2016 16:23:06 GMT -5
Compound26, no offence meant: Do you understand why none of these people had a significant positive influence on endos picking up Afrezza? I realize that this past endorsement encouraged MNKD management to believe that sales to Afrezza would soar right after start of sales. Where were these people last year? I do not expect any individual to have a great impact on the Endos or PCPs picking up Afrezza. As for Dr. Aaron Kowalski himself, I understand that he spoke at the ADCOM from a public support point of view (i.e., we need to make more new treatment options to the diabetics). Now that he has started using Afrezza and seen its advantages and benefits, I hope his personal experience with Afrezza and deeper understanding of Afrezza will prompt him to more publicly advocate Afrezza. Because of his background (PhD, Chief Mission Officer and Vice President Research of JDRF), hopefully the Endos or PCPs will pay more attention and give more weight to what he says about Afrezza. We need more advocates like him. Sanofi has definitely done a poor job of promoting Afrezza, resulting in very low awareness of Afrezza. With enough awareness, even just prescribing Afrezza to patients with needle phobia, history of frequent hypos with RAAs, compliance issues with RAAs, uncontrollable A1Cs with RAAs, visual impairment or manual dexterity issues will be sufficient to make Afrezza a huge success. |
|
|
|
Post by cjc04 on Feb 11, 2016 18:04:43 GMT -5
Everyone that has a twitter account should favorite and re-tweet this! LOL... how would I know if the ONE person following me on twitter would be interested in this? It would seem important to get my content right because I could easily lose my ENTIRE audience with one misstep. LOL,,,, let me guess, your only follower is also MY only follower. |
|
|
|
Post by jbe on Feb 11, 2016 18:06:42 GMT -5
At least the Doctor has 1149 followers, I imagine at least some are diabetics or doctors, so this all positive.
|
|
